Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2013 (2013), Article ID 790154, 15 pages
http://dx.doi.org/10.1155/2013/790154
Review Article

Developing Multipurpose Reproductive Health Technologies: An Integrated Strategy

1Coalition for Advancing Multipurpose Innovations (CAMI)/Public Health Institute, USA
2AVAC, Global Advocacy for HIV Prevention, New York, USA
3University of California, 50 Beale Street, Suite 1200, San Francisco, CA 94105, USA
4NWJ Group, LLC, USA
5Mapp Biopharmaceutical, San Diego, USA

Received 31 October 2012; Revised 15 January 2013; Accepted 16 January 2013

Academic Editor: Craig R. Cohen

Copyright © 2013 P. F. Harrison et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Women worldwide confront two frequently concurrent reproductive health challenges: the need for contraception and for protection from sexually transmitted infections, importantly HIV/AIDS. While conception and infection share the same anatomical site and mode of transmission, there are no reproductive health technologies to date that simultaneously address that reality. Relevant available technologies are either contraceptive or anti-infective, are limited in number, and require different modes of administration and management. These “single-indication” technologies do not therefore fully respond to what is a substantial reproductive health need intimately linked to pivotal events in many women's lives. This paper reviews an integrated attempt to develop multipurpose prevention technologies—“MPTs”—products explicitly designed to simultaneously address the need for both contraception and protection from sexually transmitted infections. It describes an innovative and iterative MPT product development strategy with the following components: identifying different needs for such technologies and global variations in reproductive health priorities, defining “Target Product Profiles” as the framework for a research and development “roadmap,” collating an integrated MPT pipeline and characterizing significant pipeline gaps, exploring anticipated regulatory requirements, prioritizing candidates for problem-solving and resource investments, and implementing an ancillary advocacy agenda to support this breadth of effort.